ANGOGALENICA INDUSTRIA FARMACEUTICA SL
Company details
- No Activa NIF/CIF: B87750097
-
-
-
-
Address: Calle Carpinteros, 12, 28906 Getafe, Madrid, España See in map
-
-
Featured products:
More information on ANGOGALENICA INDUSTRIA FARMACEUTICA SL
-
02/09/2024 | BORME act no.: 379097 | Register: MADRIDCeses/Dimisiones
-
02/09/2024 | BORME act no.: 379097 | Register: MADRIDNombramientos
-
02/09/2024 | BORME act no.: 379097 | Register: MADRIDDisolución
-
22/03/2017 | BORME act no.: 128771 | Register: MADRIDConstitución
-
22/03/2017 | BORME act no.: 128771 | Register: MADRIDNombramientos
Other information
The CIF assigned to ANGOGALENICA INDUSTRIA FARMACEUTICA SL is B87750097, while its current business status is dissolved. The company operates in the economic sector identified by the CNAE 4646 - Comercio al por mayor de productos farmacéuticos. In addition, its activity corresponds to the SIC classification -.
The template of ANGOGALENICA INDUSTRIA FARMACEUTICA SL includes Between 1 and 9 employees, and the company reports an annual turnover of less than 2 million euros. ANGOGALENICA INDUSTRIA FARMACEUTICA SL is registered in the Mercantile Registry of Madrid and accumulates a total of 3 registration charges. The most recent announcement in Borme was published on 02/09/2024, while its last deposit of ordinary annual accounts is related to the - exercise.
If you want to obtain contact information for ANGOGALENICA INDUSTRIA FARMACEUTICA SL, such as the telephone number, postal address, or website, you can consult our Company Data module.
To access more details about ANGOGALENICA INDUSTRIA FARMACEUTICA SL, consider reviewing one of our available financial reports, the company's Annual Accounts, or verifying its outstanding payments registered in the RAI delinquency file.
The financial, commercial, and legal information provided about ANGOGALENICA INDUSTRIA FARMACEUTICA SL comes from official data sources and is automatically updated every day.
Do you want to know more about ANGOGALENICA INDUSTRIA FARMACEUTICA SL??
Find out more about this company by consulting these reports: